【摘要】 目的研究XRCC1单核苷酸多态性与晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)对以顺铂(cisplatin,DDP)或卡铂(carboplatin,CBP)为基础药物的化疗敏感性的关系。方法经病理学确诊的晚期NSCLC患者97例,采用DDP或CBP为基础药物的方案化疗,3个周期后进行疗效评价。以聚合酶链反应(PCR)结合限制性片段长度多态性(RFLP)检测XRCC1Arg194Trp和Arg399Gln基因型,并比较基因型与化疗敏感性的关系。结果(1)携带XRCC1194Arg/Trp的患者有效率高于携带Arg/Arg、Trp/Trp基因型的患者(P<0.05);携带至少一个Trp等位基因基因型患者的化疗敏感性是携带Arg/Arg基因型的3.4倍(OR=3.39,95%,CI=1.32~8.70,P<0.05)。(2)携带XRCC1399Arg/Arg、Arg/Gln、Gln/Gln基因型患者的有效率分别为36.4%、22.9%、28.6%,差异无统计学意义(P>0.05)。尚未发现XRCC1Arg194Trp和Arg399Gln基因多态性存在联合作用。结论XRCC1Arg194Trp单核苷酸多态性可能与晚期NSCLC对铂类药物的化疗敏感性相关。更多还原

【Abstract】 Objective This study examined the association between genetic polymorphisms of XRCC1 and response to cisplatin-or carboplatin-based chemotherapy of advanced non-small cell lung cancer(NSCLC).Methods Totally 97 patients with advanced NSCLC were routinely treated with cisplatin-or carboplatin-based chemotherapy,and clinical response was evaluated after 3 cycles.XRCC1 genotypes were determined by PCR-RFLP methods using DNA samples isolated from peripheral blood collected before treatment.Results(1)The response rate to the chemotherapy in patients with the XRCC1 194Arg/Trp genotype significantly higher than that in patients with the Arg/Arg、Trp/Trp genotype(P<0.05);The XRCC1 194Trp allele carriers had higher response rate than the subjects with the Arg/Arg genotype(adjusted OR=3.39,95% CI=1.32～8.70,P<0.05).There was no difference of the response rate(34.6%、27.5%,20.0%)to chemotherapy with the 399 Arg/Arg、Arg/Gln、Gln/Gln gene type(P>0.05).Furthermore,it did not appear that 194Arg/Trp and 399Arg/Arg genotypes had synergic effect on the chemotherapy efficacy.Conclusion Polymorphisms in the XRCC1 Arg194Trp may have significant impact on the response of NSCLC patients to platin-based chemotherapy.更多还原